Basic Information
| LncRNA/CircRNA Name | FTX |
| Synonyms | FTX, LINC00182, MIR374AHG, NCRNA00182 |
| Region | GRCh38_X:73946555-74293574 |
| Ensemble | ENSG00000230590 |
| Refseq | NR_028379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | RIP etc. |
| Sample | Frozen HCC tumors, cell lines (SMMC-7721, HCCLM3, Hep3B, HepG2, Huh7, 97H and GSG7701) |
| Expression Pattern | down-regulated |
| Function Description | lnc-FTX is expressed at higher levels in female livers than in male livers and is significantly downregulated in HCC tissues compared with normal liver tissues. Patients with higher lnc-FTX expression exhibited longer survival, suggesting that lnc-FTX is a useful prognostic factor for HCC patients. lnc-FTX inhibits HCC cell growth and metastasis both in vitro and in vivo. Mechanistically, lnc-FTX represses Wnt/B-catenin signaling activity by competitively sponging miR-374a and inhibits HCC cell epithelial-mesenchymal transition and invasion. In addition, lnc-FTX binds to the DNA replication licensing factor MCM2, thereby impeding DNA replication and inhibiting proliferation in HCC cells. |
| Pubmed ID | 27065331 |
| Year | 2016 |
| Title | Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a |
External Links
| Links for FTX | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |